Evgen Pharma PLC Grant of Options (5963O)
January 30 2019 - 11:28AM
UK Regulatory
TIDMEVG
RNS Number : 5963O
Evgen Pharma PLC
30 January 2019
For immediate release 30 January 2019
Evgen Pharma plc
("Evgen" or the "Company")
Grant of Options
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, announces that, on 28 January 2019, certain employees
of the Company including the following Persons Discharging
Managerial Responsibility ("PDMR") were granted nil cost options
over a total of 826,743 ordinary shares in the Company exercisable,
subject to the option vesting, for a period of up to ten years from
the date of grant under the Evgen Pharma plc Long Term Incentive
Plan ("LTIP").
PDMR Position Options granted
Dr Stephen Franklin Chief Executive Officer 471,061
------------------------- ----------------
Richard Moulson Chief Financial Officer 155,682
------------------------- ----------------
Clinical Development
Sally Ross Officer 200,000
------------------------- ----------------
The number of nil cost options awarded has been calculated by
reference to the three month weighted average share price to 28
January 2018.
These nil cost options are subject to the rules of the LTIP. The
options will vest on the third anniversary of grant subject to a
minimum absolute total shareholder return (TSR) from the grant date
to the vesting date of 10%, at which 25% of the awards will vest,
and then on a straight line basis to a 20% TSR at which 100% of the
awards will vest. Re-testing of this performance condition after
the vesting date is not permitted.
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466 5000
Dr Stephen Franklin, CEO
Richard Moulson, CFO
www.evgen.com
finnCap
Geoff Nash, Teddy Whiley (Corporate
Finance)
Alice Lane, Manasa Patil (ECM)
www.finncap.com +44 (0) 20 7220 0500
WG Partners LLP
Nigel Barnes, Claes Spång +44 (0) 20 3705 9330
Buchanan
Mark Court, Sophie Wills, Tilly
Abraham
evgen@buchanan.uk.com +44 (0) 20 7466 5000
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Steve Franklin
2 Reason for the notification
a) Position/status Chief Executive
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Evgen Pharma Plc
b) Legal Entity Identifier 213800NO3E6TSTQO8K20
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the financial instrument, type of instrument Options over ordinary shares of 0.25 pence each
GB00BSWYN304
Identification code
b) Nature of the transaction Grant of options
c) Currency GBP
d) Price(s) and volume(s) Price(s) Volume(s)
nil 471,061
e) Aggregated information
- Aggregated volume
- Price
- Aggregated total
f) Date of the transaction 28 January 2019
g) Place of the transaction London Stock Exchange, AIM
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Richard Moulson
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Evgen Pharma plc
b) Legal Entity Identifier 213800NO3E6TSTQO8K20
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the financial instrument, type of instrument Options over ordinary shares of 0.25 pence each
Identification code GB00BSWYN304
b) Nature of the transaction Grant of options
c) Currency GBP
d) Price(s) and volume(s) Price(s) Volume(s)
nil 155,682
e) Aggregated information
- Aggregated volume
- Price
- Aggregated total
f) Date of the transaction 28 January 2019
g) Place of the transaction London Stock Exchange, AIM
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Sally Ross
2 Reason for the notification
a) Position/status Clinical Development Officer
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Evgen Pharma plc
b) Legal Entity Identifier 213800NO3E6TSTQO8K20
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the financial instrument, type of instrument Options over ordinary shares of 0.25 pence each
Identification code GB00BSWYN304
b) Nature of the transaction Grant of options
c) Currency GBP
d) Price(s) and volume(s) Price(s) Volume(s)
nil 200,000
e) Aggregated information
- Aggregated volume
- Price
- Aggregated total
f) Date of the transaction 28 January 2019
g) Place of the transaction London Stock Exchange, AIM
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHSDLFWSFUSEEF
(END) Dow Jones Newswires
January 30, 2019 12:28 ET (17:28 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024